<DOC>
	<DOCNO>NCT00598169</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth block blood flow cancer . Drugs use chemotherapy , dexamethasone , ifosfamide , carboplatin , etoposide , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . It yet know whether give bortezomib together combination chemotherapy effective without rituximab treat AIDS-related non-Hodgkin lymphoma . PURPOSE : This clinical trial study give bortezomib together dexamethasone , ifosfamide , carboplatin , etoposide see well work without rituximab treat patient relapsed refractory AIDS-related non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Bortezomib , Ifosfamide , Carboplatin , Etoposide , With Without Rituximab , Treating Patients With Relapsed Refractory AIDS-Related Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate safety overall lymphoma response rate bortezomib combination ifosfamide , carboplatin , etoposide ( ICE ) without rituximab patient Epstein-Barr Virus ( EBV ) - and/or human herpes virus-8 ( HHV-8 ) - positive relapsed refractory HIV-associated non-Hodgkin lymphoma ( NHL ) . Secondary - Evaluate impact bortezomib alone combination rituximab ) ICE ( [ R ] ICE ) serum HIV viral load APOBEC3G level . - Estimate impact bortezomib alone combination ( R ) ICE EBV HHV-8 lytic activation use serum viral load . - Estimate median response duration 1 year overall survival rate patient treat regimen . - Evaluate safety bortezomib alone patient relapse refractory AIDS-associated lymphoma . - Correlate EBV/HHV-8 viral load change lymphoma response . - Compare outcomes parallel protocol employ ICE without rituximab patient EBV/HHV-8-negative AIDS-NHL ass whether bortezomib additional effect beyond ( R ) ICE alone . OUTLINE : This multicenter , dose-escalation study bortezomib . Patients assign 1 2 treatment group . - CD20-negative patient - Part A : Patients receive bortezomib IV 3-5 second day 1 8 , dexamethasone IV etoposide IV 2 hour day 8-10 , ifosfamide IV continuously 24-hours carboplatin IV 2 hour day 9 . Treatment repeat every 28 day maximum tolerate dose ( MTD ) determine . Patients tolerate MTD bortezomib may move part B . - Part B : Patients receive bortezomib IV 3-5 second MTD day 1 8 , dexamethasone IV day 1-3 8 , etoposide IV 2 hour day 1-3 , ifosfamide IV continuously 24-hours carboplatin IV 2 hour day 2 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Some patient may undergo hematopoietic stem cell transplantation ( HSCT ) . - CD20-positive patient - Part A : Patients receive bortezomib , dexamethasone , etoposide , ifosfamide , carboplatin CD20-negative patient part A group . - Part B : Patients receive rituximab IV day 1 . Patients also receive bortezomib , dexamethasone , etoposide , ifosfamide , carboplatin CD20-negative patient part B group . Some patient may undergo HSCT . Patients undergo blood sample collection periodically correlative study . Samples analyzed effect bortezomib viral activation replication via Taqman polymerase chain reaction ( PCR ) , quantification APOBEC3G level via western blot . Similar study perform BCLB-1 EBV contain line , well Daudi EBV-transformed B-lymphocyte line via quantitative viral DNA PCR . Patients complete Functional Assessment Cancer Therapy/GOG-Neurotoxicity Questionnaire , v4.0 day 8 week 4 Part A least per course Part B assessment neuropathic pain and/or peripheral neuropathy . After completion study treatment , patient achieve complete response ( CR ) follow 2-4 week every 3 month 1 year . Patients achieve CR completion study treatment decline antineoplastic treatment follow 2-4 week every 3 month 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm relapsed refractory HIVassociated nonHodgkin lymphoma ( NHL ) Must histologic cytologic documentation prior AIDSassociated NHL ( i.e. , time diagnosis ) clinically relapse and/or refractory disease biopsy feasible Must document HIV seropositivity Must documentation EpsteinBarr Virus ( EBV ) and/or human herpes virus8 ( HHV8 ) positive infection within lymphoma ( i.e. , LMP1 , LANA expression , positive EpsteinBarrencoded RNAs [ EBERs ] ) PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status ( PS ) 02 OR Karnofsky PS 50100 % Life expectancy &gt; 2 month ANC ≥ 1,000/mm³* ( growth factor support allow ) Hemoglobin ≥ 8.0 g/dL* ( growth factor support allow ) Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 mg/dL AST/ALT ≤ 2.5 time institutional upper limit normal ( ULN ) Serum creatinine ≤ ULN Creatinine clearance ≥ 50 mL/min Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception NOTE : *Patients lymphomatous involvement bone unable meet hematologic criterion allow Exclusion criterion : Peripheral neuropathy ≥ grade 2 Uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Opportunistic infection control antimicrobial suppressive therapy allow , unless investigator judge infection likely become lifethreatening set multiagent chemotherapy Symptomatic congestive heart failure Unstable angina pectoris NYHA class III IV heat failure Myocardial infarction within past 6 month Uncontrolled angina Severe uncontrolled ventricular cardiac arrhythmia Acute ischemia active conduction system abnormalities ECG Serious psychiatric medical illness , would interfere study compliance Social situation would interfere study compliance Acute active HIVassociated opportunistic infection require antibiotic treatment Mycobacterium avium candidiasis allow unless concurrent therapy moderatetostrong CYP3A4 inducer inhibitor require Chronic myelosuppressive agent therapy allow provide hematologic criterion meet Hypersensitivity compound similar chemical biological composition bortezomib , boron , mannitol , ifosfamide , carboplatin , etoposide Concurrent malignancy except carcinoma situ cervix , situ anal cancer , nonmetastatic nonmelanoma skin cancer , Kaposi 's sarcoma require systemic chemotherapy Active hepatitis B infection ( hepatitis B surface antigenpositive ) , unless 1 follow criterion meet : Able start dual antihepatitis B adefovir telbivudine therapy prior study Receiving dual antihepatitis B therapy least 12 week prior study either agent active HIV ( i.e. , entecavir , tenofovir , lamivudine , emtricitabine ) Concurrent grapefruit juice/fruit green tea PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior adverse effect due agent administer 3 week earlier Glucocorticoid therapy within past 3 week allow More 3 week since prior chemotherapy More 2 week since prior radiotherapy More 14 day since prior concurrent investigational agent ( bortezomib ) No concurrent moderatetostrong CYP3A4 inducer inhibitor protease inhibitor Concurrent stable ( least 12 week ) antiretroviral regimen allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
</DOC>